Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period

다국어 초록 (Multilingual Abstract)

Background: Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) has been associated with favorable clinical outcome in breast cancer patients. However, the possibility that the prognostic significance of pCR differs among various definitions has not been established. Methods: We retrospectively evaluated the pathologic response after NAC in 353 breast cancer patients and compared the prognoses after applying the following different definitions of pCR: ypT0/is, ypT0, ypT0/is ypN0, and ypT0 ypN0. Results: pCR was significantly associated with improved distant disease-free survival (DDFS) regardless of the definition (ypT0/is, p = .002; ypT0, p = .008; ypT0/is ypN0, p < .001; ypT0 ypN0, p = .003). Presence of tumor deposits of any size in the lymph nodes (LNs; ypN ≥ 0(i+)) was associated with worse DDFS (ypT0 ypN0 vs ypT0 ypN ≥ 0(i+), p = .036 and ypT0/is ypN0 vs ypT0/is ypN ≥ 0(i+), p = .015), and presence of isolated tumor cells was associated with decreased overall survival (OS; ypT0/is ypN0 vs ypT0/is ypN0(i+), p = .013). Residual ductal carcinoma in situ regardless of LN status showed no significant difference in DDFS or OS (DDFS: ypT0 vs ypTis, p = .373 and ypT0 ypN0 vs ypTis ypN0, p = .462; OS: ypT0 vs ypTis, p = .441 and ypT0 ypN0 vs ypTis ypN0, p = .758). In subsequent analysis using ypT0/is ypN0, pCR was associated with improved DDFS and OS in triple-negative tumors (p < .001 and p = .003, respectively). Conclusions: Based on our study results, the prognosis and rate of pCR differ according to the definition of pCR and ypT0/is ypN0 might be considered a more preferable definition of pCR.

참고문헌 (Reference)

1 Lakhani SR, "WHO classification of tumours of the breast" IARC Press 2012

2 McCready DR, "The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer" 124 : 21-25, 1989

3 Provenzano E, "Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer : recommendations from an international working group" 28 : 1185-1201, 2015

4 Liedtke C, "Response to neoadjuvant ther-apy and long-term survival in patients with triple-negative breast cancer" 26 : 1275-1281, 2008

5 Mazouni C, "Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome" 25 : 2650-2655, 2007

6 Kaufmann M, "Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006" 18 : 1927-1934, 2007

7 Kaufmann M, "Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer" 19 : 1508-1516, 2012

8 Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update" 31 : 3997-4013, 2013

9 Carey LA, "Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study" 295 : 2492-2502, 2006

10 Wolmark N, "Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18" (30) : 96-102, 2001

11 Elston CW, "Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up" 19 : 403-410, 1991

12 Cortazar P, "Pathological complete response in neoadjuvant treatment of breast cancer" 22 : 1441-1446, 2015

13 Cortazar P, "Pathological complete response and long-term clinical benefit in breast cancer : the CTNeoBC pooled analysis" 384 : 164-172, 2014

14 Corben AD, "Pathologic response and longterm follow-up in breast cancer patients treated with neoadjuvant chemotherapy : a comparison between classifications and their practical application" 137 : 1074-1082, 2013

15 Perou CM, "Molecular portraits of human breast tumours" 406 : 747-752, 2000

16 Houssami N, "Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy" 48 : 3342-3354, 2012

17 Symmans WF, "Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy" 25 : 4414-4422, 2007

18 Baselga J, "Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial" 379 : 633-640, 2012

19 Robidoux A, "Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial" 14 : 1183-1192, 2013

20 Kuroi K, "Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer" 38-48, 2006

21 Rouzier R, "Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes" 20 : 1304-1310, 2002

22 Kurosumi M, "Histopathological criteria for assessment of therapeutic response in breast cancer" 8 : 1-2, 2001

23 Goldhirsch A, "Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011" 22 : 1736-1747, 2011

24 Gianni L, "Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial" 13 : 25-32, 2012

25 Fisher B, "Effect of preoperative chemotherapy on the outcome of women with operable breast cancer" 16 : 2672-2685, 1998

26 von Minckwitz G, "Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes" 30 : 1796-1804, 2012

27 Kuroi K, "Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG" 22 : 586-595, 2015

28 Onitilo AA, "Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival" 7 : 4-13, 2009

29 Bear HD, "Bevacizumab added to neoadjuvant chemotherapy for breast cancer" 366 : 310-320, 2012

30 Edge SB, "American Joint Committee on Cancer (AJCC) cancer staging manual" Springer 2009